Rapid diagnosis of sexually transmitted infections : Joint statement of DSTIG, RKI, and PEI, as well as the reference centers for HIV, HBV, and HCV and consulting laboratories for Chlamydia, gonococci, and Treponema pallidum
In February 2019, the fourth expert meeting on rapid diagnostic tests (RDTs) for sexually transmitted infections (STI) was held at the Robert Koch Institute (RKI) in Berlin. Novel technical developments and new aspects of RDT applications were discussed by representatives from the German STI Society (DSTIG); RKI; the Paul Ehrlich Institute; national reference centers for HIV, HBV, and HCV; and reference laboratories for Chlamydia, gonococci, and Treponema pallidum.As a result of this meeting, we present a revision of the joint statement on STI diagnostics with RDTs from 2017. The Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices became effective in May 2017 and includes more stringent regulatory requirements for RDTs, mainly concerning conformity of manufacturing processes and performance characteristics of class D in vitro diagnostics (detection of HIV, HBV, HCV, and T. pallidum). Some RDTs for HIV, HCV, and T. pallidum have been evaluated in clinical studies and/or were WHO prequalified and may be used in low-threshold services. Among them are some HIV RDTs available and approved for self-testing. In addition, some HBV RDTs based on detection of HBs antigen (HBsAg) received WHO prequalification. However, false negative results may occur in samples with low HBsAg levels, as for instance in HIV-coinfected patients receiving antiretroviral therapy. For Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), antigen-based RDTs still do not allow reliable detection of infection. Only PCR-based CT/NG RDTs possess sufficient diagnostic accuracy to be used as point-of-care tests. Rapid PCR tests for NG, however, do not provide any information about antimicrobial resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz - 63(2020), 10 vom: 01. Okt., Seite 1271-1286 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Schnelltestdiagnostik sexuell übertragbarer Infektionen : Gemeinsame Stellungnahme von DSTIG, RKI, PEI sowie den Referenzzentren für HIV, HBV und HCV und Konsiliarlaboren für Chlamydien, Gonokokken und Treponema pallidum |
|---|
| Beteiligte Personen: |
Meyer, Thomas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigen test |
|---|
| Anmerkungen: |
Date Completed 02.10.2020 Date Revised 02.10.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00103-020-03218-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315027967 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315027967 | ||
| 003 | DE-627 | ||
| 005 | 20231225154025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00103-020-03218-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315027967 | ||
| 035 | |a (NLM)32930821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Meyer, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid diagnosis of sexually transmitted infections |b Joint statement of DSTIG, RKI, and PEI, as well as the reference centers for HIV, HBV, and HCV and consulting laboratories for Chlamydia, gonococci, and Treponema pallidum |
| 246 | 3 | 3 | |a Schnelltestdiagnostik sexuell übertragbarer Infektionen : Gemeinsame Stellungnahme von DSTIG, RKI, PEI sowie den Referenzzentren für HIV, HBV und HCV und Konsiliarlaboren für Chlamydien, Gonokokken und Treponema pallidum |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2020 | ||
| 500 | |a Date Revised 02.10.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In February 2019, the fourth expert meeting on rapid diagnostic tests (RDTs) for sexually transmitted infections (STI) was held at the Robert Koch Institute (RKI) in Berlin. Novel technical developments and new aspects of RDT applications were discussed by representatives from the German STI Society (DSTIG); RKI; the Paul Ehrlich Institute; national reference centers for HIV, HBV, and HCV; and reference laboratories for Chlamydia, gonococci, and Treponema pallidum.As a result of this meeting, we present a revision of the joint statement on STI diagnostics with RDTs from 2017. The Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices became effective in May 2017 and includes more stringent regulatory requirements for RDTs, mainly concerning conformity of manufacturing processes and performance characteristics of class D in vitro diagnostics (detection of HIV, HBV, HCV, and T. pallidum). Some RDTs for HIV, HCV, and T. pallidum have been evaluated in clinical studies and/or were WHO prequalified and may be used in low-threshold services. Among them are some HIV RDTs available and approved for self-testing. In addition, some HBV RDTs based on detection of HBs antigen (HBsAg) received WHO prequalification. However, false negative results may occur in samples with low HBsAg levels, as for instance in HIV-coinfected patients receiving antiretroviral therapy. For Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), antigen-based RDTs still do not allow reliable detection of infection. Only PCR-based CT/NG RDTs possess sufficient diagnostic accuracy to be used as point-of-care tests. Rapid PCR tests for NG, however, do not provide any information about antimicrobial resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antigen test | |
| 650 | 4 | |a HIV self-testing | |
| 650 | 4 | |a Lateral flow assay | |
| 650 | 4 | |a Nucleic acid amplification test | |
| 650 | 4 | |a Point of care | |
| 700 | 1 | |a Eberle, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Roß, R Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Schüttler, Christian G |e verfasserin |4 aut | |
| 700 | 1 | |a Baier, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Buder, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Kohl, Peter K |e verfasserin |4 aut | |
| 700 | 1 | |a Münstermann, Dieter |e verfasserin |4 aut | |
| 700 | 1 | |a Hagedorn, Hans-Jochen |e verfasserin |4 aut | |
| 700 | 1 | |a Nick, Sigrid |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Klaus |e verfasserin |4 aut | |
| 700 | 1 | |a Bremer, Viviane |e verfasserin |4 aut | |
| 700 | 1 | |a Mau, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Brockmeyer, Norbert H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz |d 1999 |g 63(2020), 10 vom: 01. Okt., Seite 1271-1286 |w (DE-627)NLM148923615 |x 1437-1588 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2020 |g number:10 |g day:01 |g month:10 |g pages:1271-1286 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00103-020-03218-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2020 |e 10 |b 01 |c 10 |h 1271-1286 | ||